Dissemin is shutting down on January 1st, 2025

Published in

Royal Society of Chemistry, Journal of Materials Chemistry, 15(21), p. 5729, 2011

DOI: 10.1039/c0jm04198j

Links

Tools

Export citation

Search in Google Scholar

Dendrimer–Doxorubicin conjugate for enhanced therapeutic effects for cancer

Journal article published in 2011 by Sudeshna Chandra, Sascha Dietrich, Heinrich Lang, D. Bahadur ORCID
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

An oligo(ethylene glycol)- grafted amidoaminedendrimer was synthesized and characterized by FTIR, MS, 1H and 13C NMR. The dendritic scaffold was evaluated for its potential to load doxorubicin and its release, thereafter. The interaction between drug and the dendrimer was reviewed by ζ potential, HPLC, NMR and FTIR spectroscopy. The drug encapsulation efficiency was as high as 52%. The temperature stimulated release characteristics of the DOX loaded dendrimers were studied in PBS and SBF at 37 °C (physiological temperature) and 43 °C (hyperthermic temperature). A biphasic suspension of the dendrimer–drug conjugate and a magnetic fluid entitles release of the drug under AC magnetic field which can simultaneously be used for hyperthermia treatment of cancer. The efficacy of dendrimer–DOX conjugate was evaluated in vitro against cancer cell lines and the IC50 was estimated.